---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017846"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T23:04:19.838331+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q1 net loss $11.9M, cash $241.7M; programs advance

## Summary
- Net loss $11.9M vs $14.8M YoY; R&D expense $10.4M, G&A $3.9M.
- Cash and equivalents $241.7M, expected to fund operations >2 years.
- SURF301 Phase 1/2 of TYRA-300 for FGFR3+ tumors continues enrolling patients.
- TYRA-300 development expanded into achondroplasia; IND submission targeted in 2024.
- TYRA-200 IND cleared by FDA; Phase 1 for cholangiocarcinoma on track for 2H 2023.

## SEC filing metadata
- accession: 0000950170-23-017846
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017023017846/0000950170-23-017846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017023017846/tyra-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017846
- JSON: https://secwatch.observer/filing/0000950170-23-017846.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017846.txt

## Key facts
- Earnings Releases
  Tyra Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $11.9 million.
  - Period: the quarter ended March 31, 2023
  - Net income: $11.9 million
  - Result: reported results
  source text: Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000095017023017846/0000950170-23-017846-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.